Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study.
Lucija KovacevicMarko PetroveckiLea KorsaZlatko MarusicIvo Dumic-CuleMaja PrutkiPublished in: Diagnostics (Basel, Switzerland) (2023)
This study aimed to evaluate the performance of multiparametric breast magnetic resonance imaging (mpMRI) for predicting response to neoadjuvant chemotherapy (NAC) in patients with luminal B subtype breast cancer. The prospective study included thirty-five patients treated with NAC for both early and locally advanced breast cancer of the luminal B subtype at the University Hospital Centre Zagreb between January 2015 and December 2018. All patients underwent breast mpMRI before and after two cycles of NAC. Evaluation of mpMRI examinations included analysis of both morphological (shape, margins, and pattern of enhancement) and kinetic characteristics (initial signal increase and post-initial behavior of the time-signal intensity curve), which were additionally interpreted with a Göttingen score (GS). Histopathological analysis of surgical specimens included grading the tumor response based on the residual cancer burden (RCB) grading system and revealed 29 NAC responders (RCB-0 (pCR), I, II) and 6 NAC non-responders (RCB-III). Changes in GS were compared with RCB classes. A lack of GS decrease after the second cycle of NAC is associated with RCB class and non-responders to NAC.
Keyphrases
- neoadjuvant chemotherapy
- transcription factor
- locally advanced
- genome wide analysis
- sentinel lymph node
- lymph node
- rectal cancer
- magnetic resonance imaging
- radiation therapy
- squamous cell carcinoma
- end stage renal disease
- ejection fraction
- chronic kidney disease
- phase ii study
- newly diagnosed
- prognostic factors
- high intensity
- clinical trial
- contrast enhanced
- early stage
- risk factors
- peritoneal dialysis
- study protocol